Feline infectious peritonitis (FIP) was previously a near-invariably fatal disease, but the development of antiviral treatments has transformed welfare outcomes for affected cats.
FIP caused profound welfare suffering — cats deteriorated over weeks with increasing fluid accumulation, weight loss, lethargy, and eventual death from organ failure. Supportive care extended suffering without altering the outcome. The development of effective antiviral treatment has transformed FIP from a welfare catastrophe to a manageable disease for cats whose owners can access and afford treatment. The primary current welfare challenge is access: the most effective drug (GS-441524) is not yet licensed in the UK and must be sourced through compounding pharmacies or imported, creating legal and cost barriers. Advocacy for licensing and affordability of FIP antivirals is a direct animal welfare priority.